HCA Red Flag: Even the top end of Ambu's margin guidance is below analyst expectations (AI)
HC Andersen Capital
Summary
- Ambu's operating margin guidance for 2026/27 is 13 to 15%, below the analyst expectation of 15.4%, leading to potential earnings downgrades.
- The endoscopy business exceeded growth expectations with a 21.2% increase, driven by the SureSight Mobile pocket scope, now accounting for 65% of sales.
- Ambu's cash flow conversion target of above 40% was not met, with actuals around 30%, due to increased investments in production and development.
- A new share buyback program of DKK 400 million and an increased dividend are expected to lift earnings per share by approximately 1% next year.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Automatic translation: Originally published in Danish 05/11/2026, 06:11 GMT. Give feedback here.
| Red Flag · First reading of the financial statement · AI-generated content HCA Red Flag: Even the top end of Ambu's margin guidance is below analyst expectations (AI) Ambu (AMBU B) · Q4 2025/26 · November 5 The share is up 17% in three months and 30% since the earnings day in August |
Overall assessment: Negative assessment
| Positive view | Balanced | Negative view |
Ambu's operating margin guidance (EBIT as a percentage of sales) of 13 to 15% for 2026/27 vs. the expected 15.4% points to a lower opening, as earnings estimates will have to be downgraded. The endoscopy business grew by 21.2% vs. the expected 20.6%, and DKK 551 million to shareholders dampens the decline without offsetting it.
Red flags in the financial statements
Even the top end of the margin guidance is below expectations
New: 13 to 15% – Est. 15.4%
Ambu is accelerating investments ahead of product approvals and expects tariffs of 1% of sales, which is keeping the operating margin (EBIT as a percentage of sales) down. The midpoint of 14% removes around 8% of analysts' operating profit for 2026/27.
The quarter's margin disappointed despite the tariff refund
Actual 17.2% – Est. 19.0% – excluding refund 12.2%
The operating margin disappointed despite DKK 85 million in tariff refunds, and the year ended at 13.2% vs. the expected 13.6%. In August, Ambu expected the high end of 12 to 14%, so the new guidance is met with less confidence.
Cash flows are lagging behind Ambu's own target
New: ~30% – Target: above 40%
Higher investments in production and development ahead of launches are pulling cash flow conversion (free cash flow as a percentage of EBITDA) down from 39%. As a result, Ambu falls short of its target for the second consecutive year.
Green flags in the financial statements
Endoscopy grew more than expected
Actual 21.2% – Est. 20.6%
Both parts of the Endoscopy Solutions business grew by at least 21%, with Respiratory – the single-use airway scopes – driven by the SureSight Mobile pocket scope. This is the business the share is owned for, and it now accounts for 65% of sales.
Guidance for endoscopy is above analysts
New: ~15% – Est. 14.5%
Respiratory and cystoscopy (bladder scopes) will drive organic growth, and the acquired US software company TIMS Medical adds ~2.5 percentage points on top. This lifts sales estimates slightly, but not earnings.
New share buyback of DKK 400 million starting Monday
New: DKK 400 million + dividend of DKK 151 million
The share buyback corresponds to nearly 2% of the shares, and the dividend is raised to DKK 0.56 per share from DKK 0.41. This lifts earnings per share by around 1% next year.
Disclaimer: This is an HCA AI-generated research commentary based solely on the company's published financial statements. The commentary does not constitute investment consulting and should not be used as the sole basis for investment decisions. Investing in shares involves the risk of loss. Seek professional consulting. /HC Andersen Capital, October 7, November 5, 2026